Stifel raised the firm’s price target on Ultragenyx to $127 from $124 and keeps a Buy rating on the shares after the “under-the-radar” DTX401 GlucoGene trial delivered positive Phase 3 data. Heading into BLA submission in 2025, the firm is increasing its view of the program’s probability of success to 80% from 70% previously.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
- Ultragenyx price target lowered to $109 from $111 at Canaccord
- Ultragenyx price target lowered to $47 from $48 at Wedbush
Questions or Comments about the article? Write to editor@tipranks.com